Nebenwirkungen · Azacitidine Mylan
Azacitidine Mylan 25 mg/mL powder for suspension for injection · Abschnitt 4.8 · PDF-Seite 7
HOS-143859 · Präparat HOS-099060
Frequencies are defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Adverse reactions are presented in the table below according to the highest frequency observed in any of the main clinical studies.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-12T15:55:00Z · SHA-256 df3945b2675faeeecac1039237171eeac019a5d0066cb9655730f8dfec28f068 · Passage 9541dd8170fec3df55044a272538f08f31660039431b7f4ce65b0cab8469d463 · Zeichen 2299–2756 im Abschnitt